Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +44.71%
#3 ADO Protocol ADO Protocol +38.80%
#4 Prom Prom +34.38%
#5 Pons Pons +32.43%
#6 StonkBroker StonkBroker +31.49%
#7 TENDIES TENDIES +27.68%
#8 Collector Crypt Collector Crypt +27.15%
#9 龙虾 (Lobster) 龙虾 (Lobster) +21.71%
#10 Cysic Cysic +20.11%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Classement en actions #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Prix de l'action
$1.72
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$981.92M
Changement (1 jour)
-1.68%
Changement (1 an)
-41.83%
Pays
CN
Échange CARsgen Therapeutics Holdings Limited (2171)

Catégorie

Healthcare
Historique des dividendes pour CARsgen Therapeutics Holdings Limited (2171)
CARsgen Therapeutics Holdings Limited (symbole boursier : 2171) a versé un total de 0 dividendes.
Le total des dividendes (ajusté en fonction des divisions d’actions) est de : 0.00
Rendement du dividende (TTM) : 0
Versements de dividendes pour CARsgen Therapeutics Holdings Limited (2171) de 2026 à 2026
Versements annuels de dividendes
Année Dividende (ajusté pour divisions d’actions) Changez
Pas assez de données pour les dates fournies.
Liste de tous les paiements de dividendes
Année Dividende Changez
Pas assez de données pour les dates fournies.
Dividendes versés par des entreprises similaires ou concurrentes
Entreprise Nombre de paiements de dividendes Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH